alternatives to glp-1 medications for weight loss FDA approves Foundayo, an oral alternative Wegovy and Ozempic FDA approves Foundayo, an oral

Key Findings: - Increased risk of going over recommended weight gain limits - Higher chances of preterm birth (from 13% to 17%) - Rising cases of gestational diabetes (15% to 20%) - Nearly half faced high blood pressure issues While baby sizes and C-section rates remained similar, the impact on maternal health is significant

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for diabetes and obesity, exhibit pleiotropic effectsincluding anti-inflammatory, ...

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic poly-peptide (GIP, previously known as gastric inhibitory polypeptide) are key incretin

Your healthcare provider or pharmacist will give you instructions on how and where to self-administer the injection

SAN DIEGO(March 10, 2025)Glucagon-like peptide-1 receptor agonists (GLP-1 agonists), such as semaglutide (e.g., Ozempic), have helped improve the management of type 2 diabetes and obesity

This is where wellness starts to collide with pharma